centered image

EMA Panel Backs Netarsudil for Elevated Intraocular Pressure

Discussion in 'Ophthalmology' started by Hadeel Abdelkariem, Sep 23, 2019.

  1. Hadeel Abdelkariem

    Hadeel Abdelkariem Golden Member

    Joined:
    Apr 1, 2018
    Messages:
    3,448
    Likes Received:
    21
    Trophy Points:
    7,220
    Gender:
    Female
    Practicing medicine in:
    Egypt

    The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) recommended marketing authorization for netarsudil ophthalmic solution 0.02% (Rhokiinsa; Aerie Pharmaceuticals) for the treatment of adults with glaucoma or ocular hypertension.

    [​IMG]

    The full indication is "reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension."

    Netarsudil is a Rho kinase inhibitor that increases outflow of aqueous humor via the trabecular outflow pathway and reduces episcleral venous pressure.

    Netarsudil ophthalmic solution 0.02% will be sold as an eyedrop solution containing 200 µ/mL.


    "We are delighted that the CHMP has adopted a positive opinion for Rhokiinsa," Vicente Anido Jr, PhD, chairman and chief executive officer at Aerie, said in a company news release.

    Netarsudil ophthalmic solution 0.02% was approved by the US Food and Drug Administration December 18, 2017, and is currently marketed as Rhopressa in the United States.

    The company said it expects a decision from the European Commission in approximately 2 months; that decision will apply to all European Union member states plus Iceland, Liechtenstein, and Norway.

    Source
     

    Add Reply

Share This Page

<